Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.26 CNY
162.53 M CNY
717.61 M CNY
About R&G PHARMASTUDIES
Sector
Industry
CEO
Jie Wu
Website
Headquarters
Beijing
Founded
2008
ISIN
CNE100005K44
FIGI
BBG00D77W7H9
R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. It offers drug clinical research and development full process services for pharmaceutical companies and scientific research institutions. Its business activities include clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services. The company was founded by Jie Wu and Shu Qi Li on August 22, 2008 and is headquartered in Beijing, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 301333 is 58.41 CNY — it has decreased by −2.81% in the past 24 hours. Watch R&G PHARMASTUDIES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SZSE exchange R&G PHARMASTUDIES stocks are traded under the ticker 301333.
301333 stock has fallen by −3.45% compared to the previous week, the month change is a 11.43% rise, over the last year R&G PHARMASTUDIES has showed a −15.59% decrease.
We've gathered analysts' opinions on R&G PHARMASTUDIES future price: according to them, 301333 price has a max estimate of 66.50 CNY and a min estimate of 65.00 CNY. Watch 301333 chart and read a more detailed R&G PHARMASTUDIES stock forecast: see what analysts think of R&G PHARMASTUDIES and suggest that you do with its stocks.
301333 reached its all-time high on Mar 8, 2023 with the price of 83.68 CNY, and its all-time low was 33.05 CNY and was reached on Jul 5, 2024. View more price dynamics on 301333 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
301333 stock is 4.39% volatile and has beta coefficient of 1.59. Track R&G PHARMASTUDIES stock price on the chart and check out the list of the most volatile stocks — is R&G PHARMASTUDIES there?
Yes, you can track R&G PHARMASTUDIES financials in yearly and quarterly reports right on TradingView.
R&G PHARMASTUDIES is going to release the next earnings report on Apr 28, 2025. Keep track of upcoming events with our Earnings Calendar.
301333 net income for the last quarter is 25.91 M CNY, while the quarter before that showed 35.46 M CNY of net income which accounts for −26.94% change. Track more R&G PHARMASTUDIES financial stats to get the full picture.
Yes, 301333 dividends are paid annually. The last dividend per share was 0.20 CNY. As of today, Dividend Yield (TTM)% is 0.34%. Tracking R&G PHARMASTUDIES dividends might help you take more informed decisions.
R&G PHARMASTUDIES dividend yield was 0.31% in 2023, and payout ratio reached 11.81%. The year before the numbers were 0.30% and 13.22% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 24, 2024, the company has 2.04 K employees. See our rating of the largest employees — is R&G PHARMASTUDIES on this list?
Like other stocks, 301333 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade R&G PHARMASTUDIES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So R&G PHARMASTUDIES technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating R&G PHARMASTUDIES stock shows the strong buy signal. See more of R&G PHARMASTUDIES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.